Business Update Neutral

2026-05-29 21:21

Biocon Limited issued a Corrigendum to its Postal Ballot Notice dated May 07, 2026, concerning the preferential issuance of equity shares. Following advice from Stock Exchanges, the company revised the floor price to ₹373.08 per equity share and the issue price to ₹376.41 per equity share. A total of 8,786,362 equity shares are proposed to be issued with a swap ratio of 0.76159 shares for every 100 Biocon Biologics Limited shares.

Business Update Neutral

2026-05-27 16:33

Biocon Limited announced a scheduled meeting with analyst(s)/institutional investor(s) on June 03, 2026. The management will engage with a group from Investec US Pharma & Healthcare Bus Tour in the USA. The company clarified that no Unpublished Price Sensitive Information (UPSI) will be disclosed during this meeting.

Routine Neutral

2026-05-21 19:04

New Filing detected. See link for details.

Business Update Neutral

2026-05-21 16:00

Biocon Limited announced that its management will participate in two investor conferences in Mumbai: the Morgan Stanley India Investment Forum 2026 on June 2, 2026, and the ICICI Securities India Investor Conference 2026 on June 8, 2026. The company stated that no Unpublished Price Sensitive Information will be disclosed during these meetings.

Business Update Positive

2026-05-14 16:31

Management anticipates progressive performance improvement in FY27, with new product launches scaling up significantly in the second half, particularly for biosimilars like Aspart and aflibercept in the U.S. The major investment phase is largely complete, shifting focus to execution, operating leverage, and value creation, with no need for large greenfield capex. The company achieved substantial deleveraging, reducing net debt from over $1.5 billion to $1.1 billion, with free cash flow primarily allocated to debt reduction and realizing interest cost savings (INR70-75 crores/quarter) from FY27. Generics aim for improved profitability and scaling up GLP-1 revenues, while CRDMO focuses on stable performance. Credit ratings have also been upgraded.

Business Update Positive

2026-05-11 08:34

Biocon Pharma Limited, a subsidiary of Biocon Limited, has received Health Canada approval for Micafungin for Injection, USP, 50 MG and 100 MG. This product is indicated for treating various Candidiasis infections and for prophylaxis in patients undergoing hematopoietic stem cell transplantation, strengthening Biocon's biosimilars and generics portfolio.

Governance Neutral

2026-05-09 01:21

Biocon Limited issued a Postal Ballot Notice seeking shareholder approval for several resolutions. These include revising the remuneration of Executive Chairperson Ms. Kiran Mazumdar-Shaw to not exceed ₹21 crores per annum from Biocon (and ₹25 crores total with Syngene), appointing Mr. Shreehas Pradeep Tambe as CEO & MD for five years effective April 01, 2026, and approving the issuance of equity shares on a preferential basis. The notice also covers the appointment and re-appointment of various directors. E-voting is open from May 09, 2026, to June 07, 2026, with results by June 09, 2026.

Business Update Neutral

2026-05-08 21:40

Biocon Limited has provided links to the audio and video recording of its Q4 FY26 Earnings Call, conducted on May 08, 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The recordings are accessible on the company's investor relations website.

Governance Positive

2026-05-07 23:42

Biocon's Board met on May 07, 2026, approving FY26 audited financial results and recommending a final dividend of Re. 0.50 per share. Key decisions included the appointment of S. R. Batliboi & Associates LLP as new Statutory Auditors, re-appointments and new appointments of Independent and Non-Executive Directors (partially driven by Biocon Biologics integration). The Board also approved acquiring the remaining ~2% equity in Biocon Biologics for up to ₹330.73 Crores through a preferential share issue, converting BBL's OCDs/CCDs into equity, and implementing a Long-Term Incentive Plan. The 48th AGM is scheduled for August 06, 2026.

Financials Positive

2026-05-07 23:39

Biocon reported consolidated Q4FY26 Operating Revenue of ₹4,517 Cr, up 10% YoY. EBITDA grew 29% YoY to ₹1,073 Cr, with EBITDA Margin expanding to 23% from 20% in Q4FY25 (▲300bps). Net Profit (before exceptional items) increased 64% YoY to ₹179 Cr. The Board recommended a final dividend of Re. 0.50 per share for FY26.

Governance Positive

2026-05-07 23:36

Biocon's Board approved Q4/FY26 financial results and recommended a final dividend of Re. 0.50 per share. New Statutory Auditors, S. R. Batliboi & Associates LLP, were appointed. The Board approved the re-appointment of one Independent Director and appointment of six new Directors, including five Independent Directors, to strengthen the board post-Biocon Biologics integration. The company also approved acquiring the remaining ~2% equity in Biocon Biologics Limited (BBL) for up to Rs. 330.73 Cr and a new Long-Term Incentive Plan.

Governance Positive

2026-05-07 23:36

Biocon's Board approved FY26 audited financial results and recommended a final dividend of Re. 0.50 per share (10%). The company will acquire the remaining ~2% equity in Biocon Biologics Limited for up to Rs. 330.73 Crores via preferential issue, and convert existing OCDs/CCDs into BBL equity. Other approvals include new statutory auditors (M/s. S. R. Batliboi & Associates LLP), new Senior Management Personnel, and several Director appointments/re-appointments to integrate Biocon Biologics. The 48th AGM is scheduled for August 06, 2026.

Routine Neutral

2026-05-07 23:36

New Filing detected. See link for details.

Governance Positive

2026-05-07 23:33

Biocon's Board approved audited financial results for Q4 & FY ended March 31, 2026, and recommended a final dividend of Re. 0.50 per equity share. The Board approved the appointment of S. R. Batliboi & Associates LLP as new Statutory Auditors, designated new Senior Management Personnel, and appointed multiple new Independent and Non-Executive Directors. Crucially, the Board approved the acquisition of the remaining ~2% equity shares of Biocon Biologics Limited (BBL) for approximately ₹330.73 Crores, aiming for full integration and value maximization.

Governance Positive

2026-05-07 23:33

Biocon's Board approved Q4 & FY26 financial results (details enclosed separately) and recommended a final dividend of Re. 0.50 per share for FY26. The Board also approved the appointment of S. R. Batliboi & Associates LLP as new Statutory Auditors, replacing the retiring B S R & Co. LLP. Key strategic approvals include acquiring the remaining ~2% stake in Biocon Biologics Limited for up to ₹330.73 Crores and converting BBL's debentures into equity shares. New directors and senior management were appointed, and a Long-Term Incentive Plan was approved. The AGM is set for August 06, 2026.

Governance Positive

2026-05-07 23:33

The Board approved audited financial results for Q4/FY ended March 31, 2026, and recommended a final dividend of Re. 0.50 per share. It approved the acquisition of the remaining ~2% equity in Biocon Biologics for Rs. 330.73 Crores via a preferential issue. New statutory auditors, S. R. Batliboi & Associates LLP, were recommended. Several director appointments/re-appointments were approved, including 5 new Independent Directors, and a Long-Term Incentive Plan for employees. The 48th AGM will be held on August 06, 2026.

Governance Neutral

2026-05-06 21:40

Biocon Limited clarified a news report from May 06, 2026, which claimed Ms. Kiran Mazumdar-Shaw chose her niece, Claire Mazumdar, as successor. The company confirmed that Ms. Kiran Mazumdar-Shaw continues to serve as the Executive Chairperson and is not stepping down. Biocon stated there are no impending changes in executive management or material information regarding ownership succession requiring disclosure under SEBI Regulations.

Governance Neutral

2026-05-06 21:40

Biocon Limited clarified a news report alleging Ms. Kiran Mazumdar-Shaw was stepping down as Executive Chairperson and had chosen a successor. The company stated that Ms. Kiran Mazumdar-Shaw continues in her role and there are no impending changes in executive management or ownership succession that require disclosure. Biocon reiterated its strong professional leadership and commitment to governance.

Business Update Neutral

2026-04-30 08:28

Biocon Limited announced that the U.S. FDA completed a Pre-License Inspection at its Bengaluru biosimilars site (April 20-29, 2026), issuing a Form 483 with five observations. The company clarified these observations are procedural, do not involve data integrity or quality oversight, and are not repeat findings. Biocon will submit a corrective action plan to address them.

Financials Neutral

2026-04-23 20:11

Biocon announced a Board Meeting on May 07, 2026, to approve audited Q4 FY26 financial results and consider dividend. An Earnings Conference Call for analysts and investors is scheduled for May 08, 2026. The trading window is closed from April 01 to May 09, 2026.

Business Update Positive

2026-04-21 08:49

Biocon announced Health Canada approval for Bosaya™ (Denosumab) and Vevzuo™ (Denosumab) on April 3, 2026. These biosimilars to Prolia® and Xgeva® expand access to high-quality therapies for osteoporosis and cancer-related bone conditions, strengthening Biocon's portfolio.

Routine Neutral

2026-04-20 20:33

Biocon Limited issued a reminder on April 20, 2026, to shareholders holding physical shares to update their KYC details as per SEBI Master Circular dated Feb 06, 2026. Failure to comply may lead to withholding of dividend payments.

Business Update Positive

2026-04-08 08:41

Biocon Pharma Limited, a subsidiary of Biocon Limited, received U.S. FDA approval for Dapagliflozin Tablets, 5 mg and 10 mg. The product is indicated for the treatment of adults with type 2 diabetes mellitus, strengthening Biocon's diabetes portfolio.

Business Update Positive

2026-04-07 21:01

Biocon Limited will participate in an HSBC Global Investment Summit in Hong Kong on April 14-15, 2026, and an Investor Roadshow in Singapore on April 16-17, 2026, to engage with analysts and institutional investors. No UPSI will be disclosed.

Routine Neutral

2026-04-07 20:46

Biocon Limited filed a certificate under Regulation 74(5) for the quarter ended March 31, 2026, confirming the dematerialization and rematerialization of securities as per SEBI regulations. KFin Technologies, the RTA, provided the necessary confirmation for this routine compliance.

Business Update Positive

2026-04-07 16:09

Biocon announced the U.S. commercial launch of Bosaya™ and Aukelso™, denosumab biosimilars, for osteoporosis and bone metastasis. FDA approved with interchangeable designation in September 2025. This expands Biocon's portfolio in a market that saw $5 billion in denosumab sales in 2024, addressing significant unmet medical needs.

Routine Neutral

2026-03-30 13:12

Biocon Limited announced that its step-down subsidiary, Biosimilar Collaborations Ireland Limited (a subsidiary of Biocon Biologics Limited), has changed its name to Biocon Biologics Ireland Limited, effective March 27, 2026.

Governance Neutral

2026-03-27 12:19

Biocon Limited announced an amendment to its Employees Welfare Trust Deed. Two trustees, Mr. Krishnachar Nandakumar and Ms. Maninder Kapoor Puri, will resign effective March 31, 2026. Mr. Mukesh Kamath and Mr. Naveen Narayanan have been appointed as new trustees, effective April 1, 2026.

Governance Positive

2026-03-27 12:08

Biocon Limited announced the appointment of Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. Kedar Upadhye was also appointed Chief Financial Officer. These appointments are part of the strategic full integration of Biocon Biologics Limited as a wholly owned subsidiary to strengthen the company's global leadership.

Governance Negative

2026-03-27 12:06

CRITICAL RED FLAG DETECTED

Biocon's Board approved the resignation of CEO & MD Mr. Siddharth Mittal and Interim CFO Mr. Mukesh Kamath, effective March 31, 2026. Mr. Shreehas Pradeep Tambe was appointed new CEO & MD, and Mr. Kedar Narayan Upadhye as new CFO, effective April 1, 2026. Other KMP and senior management changes were also approved.

Governance Neutral

2026-03-27 12:04

CRITICAL RED FLAG DETECTED

Biocon's Board approved CEO & MD Mr. Siddharth Mittal and Interim CFO Mr. Mukesh Kamath's resignations (transitioning within group) effective March 31, 2026. Mr. Shreehas Pradeep Tambe was appointed new CEO & MD and Mr. Kedar Narayan Upadhye new CFO, effective April 1, 2026, amidst other KMP/SMP changes.

Governance Neutral

2026-03-27 11:59

CRITICAL RED FLAG DETECTED

Biocon's Board approved leadership changes. Mr. Siddharth Mittal resigned as CEO & MD and Mr. Mukesh Kamath as Interim CFO, transitioning to other group roles. Mr. Shreehas Pradeep Tambe was appointed new CEO & MD and Mr. Kedar Narayan Upadhye as new CFO, effective April 1, 2026, along with other KMP changes.

Governance Neutral

2026-03-27 11:55

CRITICAL RED FLAG DETECTED

Biocon's Board accepted CEO & MD Mr. Siddharth Mittal's and Interim CFO Mr. Mukesh Kamath's resignations, effective March 31, 2026, for new group roles. Mr. Shreehas Pradeep Tambe was appointed CEO & MD, and Mr. Kedar Narayan Upadhye as CFO, effective April 1, 2026, amid other KMP changes.

Routine Neutral

2026-03-26 18:09

Biocon Limited intimated the closure of its trading window from April 01, 2026, until 48 hours after declaration of financial results for the quarter and year ending March 31, 2026, as per SEBI PIT Regulations.

Business Update Positive

2026-03-12 21:22

Biocon Pharma Limited, a subsidiary of Biocon, received US FDA approval for Liraglutide Injection (gVictoza®) for Type 2 Diabetes Mellitus. This approval strengthens Biocon's portfolio of complex drug products, following a prior approval for gSaxenda® in February 2026.

Business Update Neutral

2026-03-05 15:51

Biocon Limited announced its management will participate in JP Morgan's annual flagship India Credit Investor Trip on March 11, 2026. This will be a group virtual interaction with analysts and institutional investors, with no Unpublished Price Sensitive Information (UPSI) to be disclosed.

Business Update Neutral

2026-03-03 23:10

Biocon Limited acquired 11,53,44,285 and 20,00,00,000 Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) of Rs. 10/- each in its wholly-owned subsidiaries, Biocon Biosphere Limited and Biocon Pharma Limited, respectively, for ongoing business, working capital, and capex requirements.

Business Update Neutral

2026-03-02 17:01

Biocon Limited announced the schedule of meetings with analysts/institutional investors. The company's management will participate virtually in the Goldman Sachs India Pharma Corporate Days on March 06, 2026, for a group interaction.

Business Update Neutral

2026-02-25 06:43

Biocon Limited filed an Investor Presentation for Analyst(s)/Institutional Investor(s) meets scheduled on February 25 and 26, 2026. The presentation provides updates on the company's business and outlook.

Business Update Positive

2026-02-24 21:04

Biocon Limited announced on February 24, 2026, that it received U.S. FDA approval for its weight management drug, Liraglutide Injection (gSaxenda®). The company views this as a defining milestone and a significant growth driver, with the U.S. market for GLP-1 in weight loss estimated at US $127 million by Dec 2025.

Business Update Positive

2026-02-17 17:22

Biocon's Q3 FY26 Earnings Call transcript discusses the strategic merger of Biocon Biologics, debt retirement, and strengthened balance sheet. Highlights include new biosimilar oncology assets, generic Liraglutide launch in EU, and a Semaglutide out-licensing deal, projecting sustainable growth and margin expansion.

Business Update Neutral

2026-02-17 16:51

Biocon's management will meet analysts/institutional investors at the IIFL 17th Entrepreneurial India Conference on Feb 25, 2026, and the Kotak Chasing Growth Conference on Feb 26, 2026, in Mumbai. No UPSI will be disclosed during these interactions.

Business Update Neutral

2026-02-13 15:37

Biocon Limited announced the availability of the audio and video recording of its Q3 FY26 Earnings Call, conducted on February 13, 2026. The recording is available on the company's website for investor information.

Business Update Positive

2026-02-13 08:25

Biocon Limited's Q3 FY26 Earnings Call Presentation on February 13, 2026, highlights a pivotal transformation, a unified global biopharma platform with a strengthened balance sheet, and a portfolio positioned for high-growth segments. The company anticipates an operational and financial inflection point leading to sustainable growth and margin expansion.

Business Update Positive

2026-02-12 19:47

Biocon Limited submitted the Monitoring Agency Report for the quarter ended December 31, 2025, issued by India Ratings & Research. The report confirmed no deviation from the stated objects for the utilization of proceeds raised through Qualified Institutions Placement (QIP).

Financials Positive

2026-02-12 19:44

Consolidated Revenue ₹4,290Cr vs ₹3,856Cr (▲11% YoY), EBITDA ₹951Cr vs ₹787Cr (▲21% YoY), PAT ₹144Cr vs ₹25Cr (▲475% YoY). EBITDA Margin 22% vs 20% (▲200bps).

Financials Negative

2026-02-12 19:29

Consolidated Revenue ₹4,173Cr vs ₹3,821Cr (▲9% YoY), EBITDA ₹540Cr vs ₹770Cr (▼30% YoY), PAT a loss of ₹52Cr vs a profit of ₹81Cr (▼164% YoY). EBITDA Margin 13% vs 20% (▼721bps). The Board also approved in-principle acquisition of remaining ~2% stake in Biocon Biologics Limited to make it a wholly owned subsidiary.

Financials Positive

2026-02-12 19:15

Consolidated Revenue ₹4,173Cr vs ₹3,821.4Cr (▲9.2% YoY), EBITDA ₹833.5Cr vs ₹751.8Cr (▲10.9% YoY), PAT ₹143.8Cr vs ₹25.1Cr (▲472.9% YoY). EBITDA Margin 20.0% vs 19.7% (▲30bps).

Financials Negative

2026-02-12 19:11

Consolidated Revenue ₹4,173Cr vs ₹3,821Cr (▲9.20% YoY), EBITDA ₹951Cr vs ₹786Cr (▲20.88% YoY), PAT (₹52Cr) vs ₹81Cr (▼-163.99% YoY). EBITDA Margin 22.78% vs 20.58% (▲220bps). PAT was impacted by an exceptional loss of ₹293Cr.

Business Update Positive

2026-02-07 13:04

Biocon Biologics announced that Fitch Ratings has upgraded the outlook on its Long-Term Foreign-Currency Issuer Default Rating (IDR) from 'Stable' to 'Positive', while affirming the IDR at 'BB-'. This reflects an expectation of sustained reduction in financial leverage following a recent equity issuance.

BIOCON

Biocon Limited

Filing History

Unlock Full History